HC Wainwright Has Positive Estimate for CRDL Q3 Earnings

Cardiol Therapeutics Inc. (NASDAQ:CRDL) – Analysts at HC Wainwright raised their Q3 2026 earnings per share (EPS) estimates for shares of Cardiol Therapeutics in a research note issued on Thursday, August 13th. HC Wainwright analyst B. Folkes now expects that the company will post earnings per share of ($0.06) for the quarter, up from their previous forecast of ($0.08). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Cardiol Therapeutics’ current full-year earnings is ($0.24) per share. HC Wainwright also issued estimates for Cardiol Therapeutics’ Q4 2026 earnings at ($0.06) EPS, FY2026 earnings at ($0.24) EPS, FY2027 earnings at ($0.30) EPS, FY2028 earnings at $0.29 EPS, FY2029 earnings at $0.61 EPS and FY2030 earnings at $1.25 EPS.

Cardiol Therapeutics (NASDAQ:CRDL) last released its earnings results on Thursday, August 13th. The company reported ($0.04) earnings per share for the quarter, beating the consensus estimate of ($0.09) by $0.05.

CRDL has been the topic of several other research reports. Canaccord Genuity Group upped their price objective on Cardiol Therapeutics from $8.00 to $10.00 and gave the company a “buy” rating in a research report on Monday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Cardiol Therapeutics in a research report on Wednesday, June 24th. Finally, Wall Street Zen raised shares of Cardiol Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, Cardiol Therapeutics has a consensus rating of “Hold” and a consensus target price of $9.50.

Cardiol Therapeutics Trading Up 5.3%

Shares of NASDAQ:CRDL opened at $1.90 on Monday. Cardiol Therapeutics has a 12 month low of $0.88 and a 12 month high of $1.94. The company has a market capitalization of $219.61 million, a price-to-earnings ratio of -7.58 and a beta of 0.72. The firm’s 50-day moving average is $1.21 and its 200 day moving average is $1.20.

Hedge Funds Weigh In On Cardiol Therapeutics

A number of large investors have recently added to or reduced their stakes in the company. Royal Bank of Canada lifted its position in shares of Cardiol Therapeutics by 62.3% during the first quarter. Royal Bank of Canada now owns 21,648 shares of the company’s stock valued at $29,000 after buying an additional 8,306 shares during the last quarter. Security National Bank of Sioux City Iowa IA acquired a new position in shares of Cardiol Therapeutics during the fourth quarter valued at about $31,000. Simplex Trading LLC raised its position in shares of Cardiol Therapeutics by 96.9% in the 4th quarter. Simplex Trading LLC now owns 32,197 shares of the company’s stock valued at $31,000 after purchasing an additional 15,842 shares during the last quarter. Boyer Financial Services Inc. acquired a new position in shares of Cardiol Therapeutics in the 4th quarter valued at $33,000. Finally, Bank of America Corp DE raised its stake in Cardiol Therapeutics by 136.2% in the 2nd quarter. Bank of America Corp DE now owns 26,455 shares of the company’s stock worth $36,000 after acquiring an additional 15,255 shares during the last quarter. 12.49% of the stock is currently owned by institutional investors.

Cardiol Therapeutics Company Profile

Cardiol Therapeutics Inc (NASDAQ: CRDL) is a clinical-stage pharmaceutical company dedicated to developing immunomodulatory treatments for patients with cardiovascular disease. The company’s lead asset, CardiolRx, is a proprietary, pharmaceutical-grade cannabidiol (CBD) formulation designed to target the inflammation and oxidative stress underlying conditions such as acute myocardial injury and heart failure. Cardiol holds exclusive global rights to CardiolRx through a licensing partnership and is advancing additional preclinical programs focused on small-molecule immunotherapies for heart disease.

CardiolRx is formulated for oral administration and has been evaluated in a randomized, placebo-controlled Phase 2 myocardial protection study assessing safety and key biomarkers following acute coronary syndromes.